CHMP adopts decided perception on unsettled MAA repayment for SYCREST sublingual tablets
Merck announced that the Board after Analeptic Products proper for Individual Manoeuvre (CHMP) adopted a encouraging evaluation on the awaiting Marketing Authorization Utilization (MAA) on the side of SYCREST® (asenapine) sublingual tablets. The CHMP has recommended that the European Commission allocate a marketing authorization championing SYCREST in the course of the treatment of manage to violent manic episodes associated with bipolar I disease in adults. The CHMP did not prop up an augury in spite of the treatment of schizophrenia.
“We are satisfied that, in the offing a decisive Commission settlement, physicians in European markets may participate in a unique opportunity to navy their patients by the symptoms of bipolar I disorder”
SYCREST is an incomparable antipsychotic medication that Merck markets as SAPHRIS® (asenapine) sublingual tablets in the Allied States. SAPHRIS was approved around the FDA on August 13, 2009 with indications for the sake of the incisive treatment of schizophrenia in adults and fitting for the exquisite treatment of manic or opposite involved episodes associated with bipolar I untidiness with or without psychotic features in adults.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
